- |||||||||| lomibuvir (VX 222) / Trek Therapeutics, Metopirone (metyrapone) / HRA Pharma, Torisel (temsirolimus) / Pfizer
Preclinical, Journal: Drug repurposing approach against chikungunya virus: an in vitro and in silico study. (Pubmed Central) - May 18, 2023
Furthermore, in silico molecular docking studies performed by targeting CHIKV structural and non-structural proteins revealed that these drugs can bind to structural protein targets such as envelope protein, and capsid, and non-structural proteins NSP2, NSP3 and NSP4 (RdRp). Findings from in vitro and in silico studies reveal that these drugs can suppress the infection and replication of CHIKV and further in vivo studies followed by clinical trials are warranted.
- |||||||||| cipargamin (KAE609) / Novartis, TD-6450 / Innoviva, Trek Therapeutics
Journal: Safe drugs with high potential to block malaria transmission revealed by a spleen-mimetic screening. (Pubmed Central) - Apr 12, 2023
P1
Pharmacokinetic modelling showed that these concentrations can be reached in the plasma of subjects receiving short courses of TD-6450. This physiologically relevant screen identified multiple mechanisms of action, and safe drugs with strong potential as malaria transmission-blocking agents which could be rapidly tested in clinical trials.
- |||||||||| lomibuvir (VX 222) / Trek Therapeutics, Vitekta (elvitegravir) / Japan Tobacco, Gilead
FDA event, Preclinical, Journal: A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2. (Pubmed Central) - Oct 28, 2022
Results revealed that five compounds, viz., resveratrol, doxorubicin, lomibuvir, elvitegravir, and enalaprilat, have significant anti-DENV activity. Further, molecular docking studies showed that these drugs can interact with a variety of protein targets of DENV, including the glycoprotein, the NS5 RdRp, NS2B-NS3 protease, and NS5 methyltransferase The in vitro and in silico results, therefore, reveal that these drugs have the ability to decrease DENV-2 production, suggesting that these drugs or their derivatives could be attempted as therapeutic agents against DENV infections.
- |||||||||| TD-6450 / Innoviva, Trek Therapeutics
Enrollment closed, Combination therapy: A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection (clinicaltrials.gov) - Jan 30, 2017
P2, N=25, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| TD-6450 / Innoviva, Trek Therapeutics
Trial completion, Phase classification, Combination therapy: A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Jan 30, 2017
P2a, N=16, Completed,
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Phase classification: P2 --> P2a
- |||||||||| TD-6450 / Innoviva, Trek Therapeutics
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Apr 28, 2016
P2, N=16, Active, not recruiting,
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=24 --> 16 | Trial primary completion date: Jul 2016 --> Nov 2016
- |||||||||| TD-6450 / Innoviva, Trek Therapeutics
Trial completion: TD-6450 MAD Study in HCV Infected Subjects (clinicaltrials.gov) - Dec 6, 2014
P1, N=47, Completed,
Recruiting --> Active, not recruiting | N=24 --> 16 | Trial primary completion date: Jul 2016 --> Nov 2016 Recruiting --> Completed
- |||||||||| TD-6450 / Innoviva, Trek Therapeutics
Trial completion, Enrollment change, Trial primary completion date: TD-6450 SAD and MAD in Healthy Subjects (clinicaltrials.gov) - Sep 28, 2014
P1, N=111, Completed,
Recruiting --> Completed Recruiting --> Completed | N=140 --> 111 | Trial primary completion date: Nov 2014 --> Aug 2014
- |||||||||| TD-6450 / Innoviva, Trek Therapeutics
Enrollment open: TD-6450 MAD Study in HCV Infected Subjects (clinicaltrials.gov) - May 21, 2014
P1, N=48, Recruiting,
Recruiting --> Completed | N=140 --> 111 | Trial primary completion date: Nov 2014 --> Aug 2014 Not yet recruiting --> Recruiting
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, lomibuvir (VX 222) / Trek Therapeutics
Trial completion, Combination therapy: VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C (clinicaltrials.gov) - Feb 26, 2014
P2, N=64, Completed,
Active, not recruiting --> Terminated; Study discontinued Active, not recruiting --> Completed
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, lomibuvir (VX 222) / Trek Therapeutics
Trial completion: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis (clinicaltrials.gov) - Feb 25, 2014
P2, N=103, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| TD-6450 / Innoviva, Trek Therapeutics
Enrollment open: TD-6450 SAD and MAD in Healthy Subjects (clinicaltrials.gov) - Feb 5, 2014
P1, N=140, Recruiting,
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, lomibuvir (VX 222) / Trek Therapeutics
New P2 trial: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis (clinicaltrials.gov) - Jan 23, 2012
P2, N=103, Completed,
|
